All News
Featured Abstracts from Industry at EULAR 2021
Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Read ArticleFoot Pain Commonly Overlooked in RA
MedPage Today
Foot pain is a common but underappreciated symptom of rheumatoid arthritis (RA) and can be associated with worse disease, European researchers found.
Read Article
Towards personalized therapy in RA with @MeganHanlon4's work: the synovial macrophage sub-population CD206+CD163+ is significantly enriched in RA synovial tissue, correlated with disease activity and baseline levels predict response to therapy.
#EULAR2021 @RheumNow #OP0028
Aurelie Najm AurelieRheumo ( View Tweet)
Insights in RA and colon:
Naïve RA patients
-higher degree of intestinal permeability vs age and sex matched ctrls in colonic biopsies
-higher serum levels of bacterial translocation markers (LBP and CD14s); reduced in resp to DMARDs. #EULAR2021 @RheumNow #OP0035 @ClaireDaien
Aurelie Najm AurelieRheumo ( View Tweet)
Don’t forget to detect cardiac abnormalities in your #RA and #PsA patients! Systematic transthoracic echocardiogram show higher prevalence of diastolic dysfunction, mild mitral and pulmonary valve regurgitation vs. matched controls. #EULAR2021 @RheumNow #POS1392 https://t.co/UsvbEKBRUY
Aurelie Najm AurelieRheumo ( View Tweet)
We know smoking is ass w/ RA. How about passive 🚬? French E3N-EPIC cohort: OP0012. Prospective questionaries of 80,000F, 698 incident cases. ⬆️ risk in passive childhood and adult tobacco exposure. #EULAR2021 @RheumNow 🚭! https://t.co/1Rf0euz3VC
Eric Dein ejdein1 ( View Tweet)
Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9
Richard Conway RichardPAConway ( View Tweet)
Dr Atienza-Mateo presents abstract #POS0595 on abatacept in RA-ILD. Abatacept surprisingly appeared to be equally good in stabilising FVC and DLCO in both UIP and NSIP patterns in RA-ILD. @RheumNow #EULAR2021 Abstr#POS0595 https://t.co/kHUxWXnaBG
Richard Conway RichardPAConway ( View Tweet)
Put out cigarettes around others!
👉passive smoking in childhood & adulthood⬆️RA risk
👉RA occurs earlier for passive smoking in childhood
👉passive smoking can cause citrullination in genetically proned subjects b/f 1st Sx's
Dr. Y Nguyen Abstr#OP0012 #EULAR2021 @rheumnow https://t.co/ZoIumNQQAf
k dao KDAO2011 ( View Tweet)
Flow&digital cytometry in early Rx-naive RA disting immunophenotypes in periph blood & dz tissue. Dr. F Rivellese Abst#OP0011
👉B cells invers correl w/inflamm'n & dz activity
👉Tph cells are potential markers of synov inflamm'n & predict clinical outcomes
#EULAR2021 @rheumnow https://t.co/5GLx0espBX
k dao KDAO2011 ( View Tweet)
#Dementia is ⬇️ing in #RheumatoidArthritis btwn 1980s & now despite theory of NSAIDs being protective for cognitive impairment & they have ⬇️ed over time vs matched pop’n. Maybe due to biological or other factors Olmsted county pop study @RheumNow @eular_org #EULAR2021 OP0216 https://t.co/qTWDtSfPt0
Janet Pope Janetbirdope ( View Tweet)
Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT
Janet Pope Janetbirdope ( View Tweet)
Do you really needs to follow labs for pts on #JAKi ? @eular_org #EULAR2021 OP0128 studied 4.5 years in #upadacitinb 6 RCTs in RA. More grade3 or 4 anemia, low lymph, neutrophils & ⬆️
Janet Pope Janetbirdope ( View Tweet)
Potential rheum board question...
True or False?
MUC5B is a promoter variant that can increase the risk for ILD in RA
Dr. A Palomaki - winner of #EULAR 2021 Abstr award #OP0007 @RheumNow https://t.co/6xKHgXSJ29
k dao KDAO2011 ( View Tweet)
ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd
Janet Pope Janetbirdope ( View Tweet)
MUC5B variant gene in 5634 RA pts had 2X ⬆️ risk of RA ILD - same gene as in IPF. Clinical relevance is unknown but could it result in a novel Rx pathway? ? Effect of sex & smoking @RheumNow @eular_org abst OP0007 #EULAR2021 https://t.co/8XpKjPFfUX
Janet Pope Janetbirdope ( View Tweet)
To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb
Janet Pope Janetbirdope ( View Tweet)
Andrew Ostor @AbbVie symposium @eular_org presented HZ vaccines are safe in RA pts with #JAKi but with Recombinant HZ vaccine humeral response - 75% in RA pts in JAKi vs 100% controls. So should we hold JAKi with Shringix & if so for 1 or 2 wks? #EULAR2021 @RheumNow https://t.co/wVOFMa9fLm
Janet Pope Janetbirdope ( View Tweet)
Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs
Janet Pope Janetbirdope ( View Tweet)
Hands-Down Rheumatology - Swollen Hands In Rheumatoid Arthritis - could be from synovitis, tenosynovitis, edema, effusion, bony hypertrophy, nodules, secondary OA. https://t.co/dRCMzgdHqf
Links:
Dr. John Cush RheumNow ( View Tweet)


